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Abstract
Background: Core outcome sets (COS) are being developed in many clinical areas to increase the quality and
comparability of clinical trial results as well as to ensure their relevance for patients. A COS represents an agreed
standardized set of outcomes that describes the minimum that should be consistently reported in all clinical trials
of a defined area. It comprises a core domain set (defining what core outcomes should be measured) and a core
measurement set (defining measurement/assessment instruments for each core domain). For pressure ulcer
prevention trials a COS is lacking. The great heterogeneity of reported outcomes in this field indicates the need for
a COS.
Methods/design: The first part of this project aims to develop a core domain set by following established
methods, which incorporates four steps: (1) definition of the scope, (2) conducting a scoping review, (3) organizing
facilitated workshops with service users, (4) performing Delphi surveys and establishing consensus in a face-to-face
meeting with different stakeholders.
Discussion: After achieving consensus on the core domain set, further work will be undertaken to determine a
corresponding core measurement set. This will lead to better pressure ulcer prevention research in the future. There
are a number of methodological challenges in the field of COS development. To meet these challenges and to
ensure a high-quality COS, the OUTPUTS project affiliates to current standards and works in close collaboration with
international experts and with existing international service user groups.
Trial registration: The OUTPUTs project is registered in the COMET database: (http://www.comet-initiative.org/
studies/details/283). Registered on 2015.
Keywords: Core domain set, Core outcome set, Pressure ulcer, Prevention, Scoping review, Delphi, Patient reported
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Background
Results of clinical trials are critical for the development
of evidence-based guidelines and decision-making at
various levels of health care delivery. The selection of
trial outcomes affects the validity, precision and clinical
applicability of the trial findings. Trial outcomes should
be biologically plausible, clinically meaningful and
perceived as relevant from multiple perspectives, e.g.
patients, informal caregivers, health professionals, pol-
icy-makers or manufacturers [1]. Further, these out-
comes need to be measured with low risk of bias [2].
However, meta-epidemiological data indicate that
outcomes and measurement methods often vary across
trials for the same condition [3, 4], are of unclear clinical
relevance [5, 6] or show selective reporting [3, 7]. Single
trials often lack standards about the selection and meas-
urement of outcomes and thus preclude meaningful
summaries of evidence for a given health intervention.
To improve the rigour of single trials, and to facilitate
meaningful evidence syntheses, standardising trial out-
comes via the development of core outcome sets (COS)
was recommended [8]. These are intended to represent
“the minimum that should be measured and reported in
all clinical trials of a specific condition” [9] and include a
core set of outcome domains (core domain set) and a
core set of measurement instruments to measure these
outcomes (core measurement set) [10]. Thus, COS ad-
dress questions about what to measure and how to
measure it.
To date, COS have been developed for various medical
conditions, such as rheumatologic conditions [11], hip
fractures [12], atopic eczema [13] and incontinence-as-
sociated dermatitis [14]. An online database of COS pro-
jects has been established by the Core Outcome
Measures in Effectiveness Trials (COMET) initiative [9],
which is growing continuously [15]. The use of the
COMET database is actively endorsed by the Cochrane
Skin–Core Outcome Set Initiative (CS-COUSIN), which
began in 2014 and comprises international, multidiscip-
linary researchers in the field of dermatology. The aim
of this initiative is to support the development and to
strengthen the quality of COS in dermatology, skin and
soft tissue research by providing methodological advice,
implementing tools for COS development and promot-
ing exchange between the COS development groups in
the field [16].
Pressure ulcers (PU) are lesions of the skin and under-
lying soft tissues caused by prolonged and/or elevated
exposure to compressive and shearing forces. In the con-
ceptual framework of Coleman et al. [17], immobility,
impaired perfusion and skin/PU status (comprising exist-
ing and previous PU and general skin status) are pro-
posed to be direct causal factors for PU development.
There are a number of other indirect causal factors such
as compromised sensory perception, diabetes mellitus,
moisture and poor nutrition, which often occur in frail
or critically ill people [17].
PUs are classified according to the visible depth of skin
and tissue damage, ranging from non-blanchable ery-
thema (category 1) to full thickness tissue loss involving
muscle tissue and juxtaposed structures (category 4) [18].
Worldwide, the prevalence of PUs ranges from 0.3 to 46%,
with highest prevalence in advanced age [19–21]. PUs can
cause symptoms including pain [22–24], exudate and
odour and compromise all areas of patient functioning,
which consequently reduce quality of life [25, 26]. More-
over, patients with PUs are at high risk for further compli-
cations, such as nosocomial infections and sepsis, and
they experience longer lengths of hospital stay [27]. Con-
sequently, PUs represent a significant financial burden to
healthcare organisations [28–30]. As PUs are considered
to be largely preventable with good assessment and care,
their occurrence is widely used as a quality indicator/pa-
tient safety parameter [31], and much effort is afforded to
their prevention in clinical practice.
PU prevention comprises different interventions to re-
duce and/or eliminate the exposure of the patient’s skin
to pressure, e.g. by allocation of pressure-redistributing
support surfaces, regular repositioning and off-loading
of highly vulnerable body sites, such as heels. Other pre-
ventive interventions target the promotion of the skin
barrier, e.g. by good skin care, the reduction of shear and
friction forces, e.g. via moving and handling activities,
application of preventive dressings or the administration
of nutritional supplementation.
An important outcome of PU prevention trials is
the measurement of PU occurrence. However, sub-
stantial cross-trial variance and within-trial risk of
bias have been noted with regard to this outcome
measure [32, 33]. Trials show variations regarding PU
classifications or methods used to determine the pres-
ence or absence of a PU (e.g. PU confirmation based
on externally reviewed photographs or independent
second skin inspection by one or multiple experts)
[32]. In a meta-analysis by Shi et al., investigating the
effect of support surfaces in reducing PU incidence,
57% of the included trials were rated as having ser-
ious or very serious limitations [34].
Furthermore, at present there is no consensus on
how to report PUs. Often, measures of PU occur-
rence, such as incidence rates, include PUs across
several categories (e.g. categories 1 to 4 or categories
2 to 4), thus combining superficial (category 1 and 2)
and deep (category 3 and 4) PUs in one outcome
measure. However, such combined estimates ignore
the different etiological pathways of PU development
and the targets of the preventive actions under ex-
perimental evaluation, e.g. interventions which mainly
Lechner et al. Trials          (2019) 20:449 Page 2 of 9
reduce friction forces may have a greater impact on
superficial ulcers rather than deep ulcers [35].
Many other PU outcomes are also reported in trials,
such as outcomes of pathophysiological changes, includ-
ing tissue oxygenation and skin barrier changes, which
have the potential to facilitate early prediction of a pre-
vention strategy’s efficacy [36–39], or outcomes related
to health care procedures and resource use. Patient-re-
ported outcomes such as pain, experienced due to the
preventive intervention or emerging before the develop-
ment of a PU, are also important [40]. However, there
are no agreed standards for which outcomes are of most
importance and which measurement instruments or
methods should be favoured. This not only complicates
the synthesis of trial results, but also hinders the devel-
opment of clear-cut evidence-based recommendations
for PU prevention and, thus, evidence-based decision-
making in clinical practice.
The overall aim of the Outcomes for Pressure Ulcer
Trials (OUTPUTs) project is to improve methodological
standards by developing a COS for the evaluation of the
clinical efficacy, effectiveness and safety of PU preven-
tion strategies. The focus of this protocol paper is the
first part of this work, to develop a core domain set. The
development of the corresponding core measurement
set will be addressed in a separate publication.
Methods/design
The process of this project follows general guidance and
standards of COS development [10] and is part of the
Cochrane Skin–Core Outcome Set Initiative [16]. This
project complies with the methodological standards of this
group [41] and also addresses the Core Outcome Set–
Standards for Development (COS-STAD) recommenda-
tions by e.g. involving service users and other stakeholders
during the consensus building process [42]. The core do-
main set will be developed by means of four main steps:
(1) defining the scope, (2) conducting a scoping review,
(3) organizing workshops with service users, and (4)
undertaking Delphi surveys and establishing consensus at
a face-to-face meeting with different stakeholders.
Project management and stakeholders involved
All steps will be planned and led by a project team
(Table 1). The members of the project team have experi-
ence in clinical and epidemiological studies, evidence
summaries, structured consensus methods and guideline
development in the field of PU prevention and/or in in-
volving service users’ perspective in PU prevention
research.
To ensure that all steps are properly addressed, a
Methodological Advisory Board was established to pro-
vide methodological advice and guidance. Members are
advanced experts of clinical research in PU prevention,
COS development (e.g. representatives of the CS-
COUSIN), evidence syntheses on PU prevention (e.g.
representatives of the Cochrane Skin or Wound
Groups), outcome assessment, service user involvement
in COS development and statistics (Table 1).
Stakeholders participating in the Delphi surveys
and the face-to-face meeting will incorporate service
users, physicians and other health professionals
representing various settings of health care,
researchers, representatives of the health care man-
agement and manufacturers. Service users are people
who have experience of being exposed to elevated
PU risk and/or suffering from a PU, or have acted,
or do currently act, as an informal caregiver for a
person at risk or with existing PU [43]. Given the
prominent role of patients’ perspective for the valid-
ity and clinical relevance of trial findings [44, 45],
early and systematic involvement of service users as
defined above is considered crucial for COS develop-
ment [46, 47]. Therefore, representatives of the Pres-
sure Ulcer Service User Network (PURSUN) [48]
from Leeds (UK) will be regularly involved through-
out the OUTPUTs project, e.g. by inviting them to
service user workshops or to participate in Delphi
surveys (see corresponding sections below).
Table 1 Project management
Project team Methodological Advisory Board
Members:
• Balzer Katrin, Germany
• Coleman Susanne, UK
• Kottner Jan, Germany
• Lechner Anna, Germany
• Muir Delia, UK
• Nixon Jane, UK
Members:
• Bagley Heather, UK
• Beeckman Dimitri, Belgium
• Chaboyer Wendy, Australia
• Cuddigan Janet, US
• Moore Zena, Ireland
• Rutherford Claudia, Australia
• Schmitt Jochen, Germany
Tasks:
• Identification of outcomes by performing a scoping review
• Conducting workshops with service users to identify outcomes not captured by scoping review
• Organizing Delphi surveys and a face-to-face meeting to find consensus on Core Domain Set
Tasks:
• Methodological
and content advice
• Participating in Delphi surveys
and face-to-face meeting
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Scope specification
Through structured discussion within the project team
and the methodological advisory board, the applicability
of the intended COS was defined as follows: the COS
should be applicable to all types of clinical trials investi-
gating the clinical efficacy or effectiveness of all types of
PU prevention interventions. The COS should be applic-
able to studies including adult patients aged ≥ 18 years.
There should be no restriction concerning the health
care setting or geographical areas.
Scoping review
The project team will undertake a scoping review to
identify and classify outcomes that may be important
in clinical trials [49]. The main characteristic of a
scoping review is that an overview of a broad topic is
given, examining the extent and variety of the evi-
dence on a topic. Compared to a systematic review, a
scoping review allows a more general question and
has less depth, but can cover a broader conceptual
range [50, 51]. Systematic searches will be carried out
in following electronic databases: Cochrane Wounds
Group/Cochrane Skin Group Cochrane Wounds
Group Specialised Register, Cochrane Central Register
of Controlled Trials, Ovid MEDLINE, Ovid EMBASE,
EBSCO CINAHL, PsychINFO, British Nursing Index,
Allied and Complementary Medicine Database, Web
of Knowledge, Clinical Trials.gov and the WHO Inter-
national Clinical Trials Registry Platform Search
Portal.
Any intervention claimed to prevent PU, including
PU risk assessment, will be eligible for inclusion. This
scoping review will include two information sources:
(i) controlled trials and systematic reviews on the effi-
cacy, effectiveness and/or safety of any PU prevention
intervention; and (ii) primary studies and systematic
reviews specifically exploring patient-reported out-
comes related to PUs or PU prevention. In addition,
full health economic evaluations and any kind of
white or position papers on outcomes relevant to the
science or practice of PU prevention will be included.
Trials reporting PU-related outcomes only as a sec-
ondary or safety outcome of interventions which pri-
marily target conditions other than PU risk will be
excluded from this review. As the main objective of
this review is to ideally cover the full scope of out-
comes used in previous studies, and not to evaluate
the quality of study results, no formal critical ap-
praisal of study quality will be conducted. The target
material will not be limited to specific health care set-
tings or target populations. For feasibility reasons,
only papers published in the English language will be
included. No restrictions will be applied in terms of
publication date, except for the primary studies on
patient-reported outcomes, which will only be consid-
ered for inclusion if they were published after 2008,
as the time period before that date is covered by a
systematic review [25].
References will be imported into the Covidence
platform (https://www.covidence.org/), which will be
used for the study selection procedures. After removal
of duplicates, the remaining references will be
assessed for eligibility by two members of the project
team using a two-step approach (title and abstract
screening followed by full-text screening). Cases of
disagreement will be solved within the project team
through discussion.
Data extraction will be carried out by two members of
the project team and cross-checked by another project
team member. Among other characteristics the follow-
ing details will be extracted: (a) bibliographic data (first
author, year of publication, country), (b) study design, (c)
setting, (d) type of interventions under evaluation, (e)
outcomes used to assess the efficacy or effectiveness of
the preventive measure, including the operational defin-
ition, if presented by the authors, as well as (f ) safety
and (g) economical outcomes. Outcomes will be ex-
tracted as presented in the primary studies and reviews.
Extracted outcomes will be classified into core areas
and associated domains following a newly developed
outcome classification system for COS [52]. A core area
reflects “an aspect of health or health condition that
needs to be measured” to assess the effects of a health
intervention [53]. It is usually understood to represent
this aspect at the most abstract level, e.g. physiological
outcomes or life impact outcomes [52], comprising sev-
eral domains which reflect the various dimensions of the
condition of interest, e.g. with regard to the affected
body structure, function or area of life impact. The pro-
ject team will develop, based on the scoping review, a
preliminary and classified longlist of domains considered
relevant for PU prevention trials, i.e. a preliminary core
domain set. Together with a complete overview of the
review results, this preliminary core domain set will be
presented to the Methodological Advisory Board for fur-
ther discussion.
Service user domain workshops
At least two facilitated workshops with service users
will take place in Leeds, UK. These workshops serve
a dual purpose. Firstly we aim to test out approaches
to describing and discussing COS development within
this group, which will inform our approach during
the later stages of the project. Secondly we will begin
to collect data around which outcomes are important
from a service user perspective. Specifically we aim to
explore service users’ views on the preliminary results
of the scoping review, identify potentially relevant
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outcomes not identified via the scoping review and
gain a greater understanding of why specified out-
comes are important to service users. Participants of
the workshops are from an established Pressure Ulcer
Research Service User Network (PURSUN UK; http://
www.pursun.org.uk/) who comprise patients and
carers with direct experience of living with PU or PU
risk.
PURSUN was set up to improve the quality of patient
and public involvement (PPI) in PU research. Collect-
ively the workshops provide the opportunity to capture
a wide range of service user perspectives to inform the
domains.
During the workshops, we will present an overview
of the OUTPUTs project, explaining the aims,
methods and preliminary results. This will be devel-
oped by an experienced PPI officer and presented in
lay terms using an accessible format. It will be sup-
ported by information about COS highlighted in the
COMET information leaflet ‘Involving patients and
the public in improving research’ [54] to explain what
an outcome is and how this could translate to PU
prevention research. The group will then split into
subgroups to discuss the service users’ understanding
of each outcome/domain identified by the scoping re-
view, its relevance for PU prevention trials and likely
concerns about measurement. In order to clarify pos-
sible uncertainties and to record the conversation in
written form, each subgroup discussion will be facili-
tated by a project member. After re-convening to the
full group, further discussion will take place and this
discussion will be audio recorded and transcribed.
The researcher will listen to the audio tapes and read
the transcripts to ensure completeness. The data will
be coded with categories based on the domains iden-
tified in the scoping review, in keeping with directed
content analysis [55]. Further codes can be added as
they emerge from the data. A summary report of the
meeting will be written and reviewed by the facilita-
tors and service user participants to ensure it reflects
group discussions. We will seek feedback from partic-
ipants at the end of the session and at a separate
PURSUN meeting. People will be asked to consider
how well the project was explained, whether they felt
able to contribute meaningfully and how best to gain
service users perspectives throughout the Delphi sur-
vey and face to face consensus meeting.
Delphi surveys
Delphi studies are an established method for formal con-
sensus development [56], consisting of iterative surveys
among a representative sample of stakeholders who are
asked to express their views both quantitatively and
qualitatively [57, 58]. Based on the results of the scoping
review and the workshops with service users, an inter-
national Delphi study will be conducted over a mini-
mum of two rounds in order to achieve preliminary
consensus about the importance of outcome domains
identified so far. A broad geographical coverage of par-
ticipating stakeholders (service users, physicians and
other health professionals, researchers, representatives of
the health care management and manufacturers) will be
targeted via links with existing professional and service
user groups.
Prior to the first Delphi round, a draft version of the
survey and supporting materials (e.g. overview of the re-
view results) will be discussed with the service users
group and the Methodological Advisory Board. Based on
discussions, the survey and supporting material will be
refined, followed by a pilot test with regard to the feasi-
bility of the survey, involving members of the service
user group.
Data will be collected via an online survey platform,
‘COMET Delphi Manager’ [59], allowing participants to
rate the relevance of the core outcome domains identi-
fied in the previous project steps on a nine-step numeric
rating scale, inspired by the GRADE working group:
scores 1 to 3 indicate outcomes of limited importance, 4
to 6 indicate outcomes of non-critical importance, and 7
to 9 indicate outcomes of critical importance [60–62].
The presentation of the outcomes to the participants will
be randomized in order to minimize risk of bias. The
participants will have the possibility to add comments
on each of the proposed outcomes. They will also be in-
vited to list additional relevant outcomes not included in
the survey.
The decision regarding which outcome should be in-
cluded in the preliminary core domain set will follow a
consensus definition already used in previous COS pro-
jects [13, 63] and favoured by the OMERACT (Outcome
Measures in Rheumatology) initiative [53, 64]. According
to this decision rule, each outcome may fall into one of
three categories: (a) consensus that the outcome should
be part of the COS (≥ 70% participants scoring 7 to 9
and ≤ 15% participants scoring 1 to 3); (b) consensus
that the outcome should not be part of the COS (≥ 70%
participants scoring 1 to 3 and ≤ 15% participants scor-
ing 7 to 9); (c) no consensus (any other scoring distribu-
tions) [10]. After the first Delphi round, a summary of
the stakeholder group’s scores and newly added out-
comes will be presented to the participants. The sum-
mary will be reviewed by service users to ensure it is
accessible and clear to lay people. The feedback of the
results of Delphi round 1 gives the participants the op-
portunity to contemplate and revise their own opinions
by rerating all outcomes in round 2. This may result in a
better agreement between the participants [65, 66]. At
the end of Delphi round 2 each outcome will be
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classified according to the consensus definition de-
scribed above. All of the outcomes falling into category
(a) will be included in the preliminary core domain set.
Outcomes falling into category (b) will be excluded and
thus will not be followed further. In case of outcomes
falling into category (c) a third Delphi round will be con-
ducted. At the end of each Delphi round, qualitative and
quantitative data will be descriptively analyzed. Qualita-
tive data analysis will follow established methods of de-
scriptive analyses in qualitative research [67, 68]. All
quantitative analyses will be conducted using IBM SPSS
Statistics 23 software. For each outcome domain de-
scriptive statistics will be determined: frequency distri-
bution, median and interquartile range (IQR), both for
the total sample and stratified per stakeholder group.
The same weight will be attributed to each participant
irrespective of the stakeholder group. To allow descrip-
tive analyses, the following socio-demographic data will
be gathered in the first Delphi round: (a) stakeholder
group, to which the person belongs to (b) country, (c)
age and gender, (d) highest degree of education, (e) ex-
perience in preventing PU.
Face-to-face meeting
Upon completion of the Delphi surveys, a face-to-face
meeting will be organized in order to reach final con-
sensus about inclusion in the core domain set. The
face-to-face meeting will be planned in accordance
with COMET guidance [69] and principles established
in previous consensus/servicer user engagement work
[70] to ensure it is accessible to service users as well
as professionals. This includes organizing the meeting
well in advance, holding it at an accessible venue,
using an expert facilitator to lead the meeting and en-
suring support for service users before, during and
after the meeting to facilitate their contribution [71].
The outcomes of unclear importance, and those rated
as being critically important, will be subject to struc-
tured discussions. Participants of the Delphi surveys
who have completed all rounds will be invited to join
the face-to-face meeting, which will take place at the
annual meeting of European Pressure Ulcer Advisory
Panel in 2020. A summary of previous results, includ-
ing an overview of how each stakeholder group has
scored the relevant outcomes, will be presented. The
participants will have the opportunity to discuss each
outcome, exchange their views and convince others.
After discussion, each outcome under debate will be
scored by the participants anonymously with the
nine-step numeric rating scale described above. To
include an outcome in the core domain set, at least
70% of the participants need to score it as critically
important [10, 72].
Discussion
The planned project follows current guidance to develop
a high-quality COS in the field of PU prevention and
deals with the first stage on developing a core domain
set. A number of methodological challenges in the field
of COS development in general [73–76], and specifically
for COS, which focus on prevention.
So far only a small number of COS exist for trials in-
vestigating preventive strategies [77–79]. In general it
seems to be more complicated to define preventive ef-
fects compared to treatment effects. One challenge will
be to ensure that all participants will have a correct un-
derstanding of the task. It may be challenging to make
clear to service users and clinicians that the outcomes
under discussion refer to clinical interventions with the
major goal of “non-occurrence”, or prevention of deteri-
oration. Confusion may be possible as a clear distinction
between preventive and treatment measures cannot al-
ways be made. Many interventions targeting prevention
of PUs, or preventing the deterioration of an existing
PU, are also important for treatment, e.g. repositioning
or the use of pressure-redistributing surfaces. This over-
lap between prevention and treatment interventions is
described by other developers of COS for prevention tri-
als as well [77, 80]. It is hoped that work in the preced-
ing service user domain workshops will facilitate clarity
about these potential areas of confusion. In addition it
will be important to impart to the participants of the
service user workshops and to the stakeholders taking
part in the Delphi surveys that a COS aims to define
outcomes for clinical trials research rather than for clin-
ical practice.
Further, there is a range of different PU prevention strat-
egies and the relevance of some outcomes is bound to the
type of intervention. For example trials analyzing the ad-
ministration of nutritional supplements often report the
outcomes total serum protein or weight gain, which are
outcomes plausible just for this type of intervention. It
may be difficult to develop a COS which meets the com-
plexity and diversity of PU preventive strategies as a
whole. At the present time it is not entirely clear whether
‘generic’ core outcomes will be developed or whether the
development of intervention-specific core outcomes will
be required [41].
In general, there is discussion of how specified
outcomes should be defined in a COS. Besides the deter-
mination of outcomes/domains and the corresponding
measurement instrument, the time frame of the outcome
measurement and the compilation of results (e.g. means,
proportions) are important as well. Moreover, uncertainty
remains about at what level of abstraction domains should
be defined (e.g. adverse events in general versus a specific
adverse event like falls or itching) [75]. To meet all these
challenges properly it is important to follow the prescribed
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process of current standards step by step. One critical fac-
tor in this process is to include content and method ex-
perts and to integrate the experience of service users as
well as of other stakeholders. Only a high-quality COS can
improve the quality of trial results and promote evidence-
based recommendations.
Limitations
The aim of the OUTPUTs project is to develop a global
COS. As the project team is Europe centred (Germany
and UK), we endeavoured to widen the geographical dis-
tribution within the Methodological Advisory Board.
However, representatives of Africa and Asia are missing.
Thus, an effort will be made to ensure a wide geograph-
ical coverage within the Delphi surveys. As only papers
in the English language will be included in the scoping
review, a possible language bias may occur. Further, al-
though the literature search will be conducted in most
relevant electronic databases, including the largest trial
registry database, some publications might not be
identified.
Future research plan
After the development of a core domain set, inquiries
for reaching evidence-based consensus on preferred
measurement tools for the defined core outcomes are
planned. This step will consist of three stages: a system-
atic review, guided workshops with service users and a
consensus-building process based on the Nominal group
technique. The aim is the publication of a COS compris-
ing a full list of included outcomes and of corresponding
measurement instruments.
Trial status
The development of the core domain set is active and
ongoing in the phase of data extraction for the scoping
review.
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